Human DNA topoisomerase IIα-dependent DNA cleavage and yeast cell killing by anthracycline analogues

Cancer Research

Volumn 58, Issue 9, 1998, Pages 1886-1892

  Binaschi, Monica ^a   Farinosi, Rosalba ^a   Austin, Caroline A ^b   Fisher, L Mark ^c   Zunino, Franco ^a   Capranico, Giovanni ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRANILIC ACID DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; IDARUBICIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CYTOTOXICITY; DNA CLEAVAGE; DRUG RETENTION; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; YEAST CELL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; COLONY COUNT, MICROBIAL; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, FUNGAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; IDARUBICIN; ISOENZYMES; MUTATION; SACCHAROMYCES CEREVISIAE; TRANSFECTION;

EID: 0032080808     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Arcamone, F. Doxorubicin. In: Anticancer Antibiotics. New York: Academic Press, 1981.
2. Arcamone, F., Animati, F., Berettoni, M., Bigioni, M., Capranico, G., Casazza, A. M., Caserini, C., Cipollone, A., De Cesare, M., Franciotti, M., Lombardi, P., Madami, A., Manzini, S., Monteagudo, E., Polizzi, D., Pratesi, G., Righetti, S. C., Salvatore, C., Supino, R., and Zunino, F. A doxorubicin disaccharide analog: apoptosis-related improvement of efficacy in vivo. J. Natl. Cancer Inst., 89: 1217-1223, 1997.
3. Arcamone, F., Animati, F., Capranico, G., Lombardi, P., Pratesi, G., Supino, R., and Zunino, F. New developments in antitumor anthracyclines. Pharmacol. Ther., 76: 117-124, 1997.
4. Capranico, G., Binaschi, M., Borgnetto, M. E., Zunino, F., and Palumbo, M. A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends Pharmacol. Sci., 18: 303-346, 1997.
5. Zunino, F., and Capranico, G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anti-Cancer Drug Des., 5: 307-317, 1990.
6. Pommier, Y. DNA topoisomerase II inhibitors. In: B. A. Teicher (ed.), Cancer Therapeutics: Experimental and Clinical Agents, pp. 153-174. Totowa, NJ: Humana Press, 1997.
7. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
8. Capranico, G., Zunino, F., Kohn, K. W., and Pommier, Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry, 29: 562-569, 1990.
9. Gupta, M., Fujimori, A., and Pommier, Y. Eukaryotic DNA topoisomerase I. Biochim. Biophys. Acta, 1262: 1-14, 1995.
10. Froelich Ammon, S. J., and Osheroff, N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem., 270: 21429-21432, 1995.
11. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 65: 635-692, 1996.
12. Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
13. Hsiang, Y. H., Lihou, M. G., and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
14. Howard, M. T., Neece, S. H., Matson, S. W., and Kreuzer, K. N. Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. Proc. Natl. Acad. Sci. USA, 91: 12031-12035, 1994.
15. DiNardo, S., Voelkel, K., and Sternglanz, R. DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc. Natl. Acad. Sci. USA, 81: 2616-2620, 1984.
16. Goto, T., and Wang, J. C. Yeast DNA topoisomerase II is encoded by a single-copy, essential gene. Cell, 36: 1073-1080, 1984.
17. Uemura, T., Ohkura, H., Adachi, Y., Morino, K., Shiozaki, K., and Yanagida, M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell, 50: 917-925, 1987.
18. Nitiss, J. L., Liu, Y. X., and Hsiung, Y. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res., 53: 89-93, 1993.
19. Jannatipour, M., Liu, Y-X., and Nitiss, J. L. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine. J. Biol. Chem., 268: 18586-18592, 1993.
20. Nitiss, J. L., Liu, Y. X., Harbury, P., Jannatipour, M., Wasserman, R., and Wang, J. C. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res., 52: 4467-4472, 1992.
21. Eng, W. K., Faucette, L., Johnson, R. K., and Sternglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol., 34: 755-760, 1988.
22. Elsea, S. H., Osheroff, N., and Nitiss, J. L. Cytotoxicity of quinulones toward eukaryotic cells: identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J. Biol. Chem., 267: 13150-13153, 1992.
23. Reid, R. J., Kauh, E. A., and Bjornsti, M. A. Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast. J. Biol. Chem., 272: 12091-12099, 1997.
24. Brown, S. J., Kellett, P. J., and Lippard, S. J. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science (Washington DC), 261: 603-605, 1993.
25. Ramotar, D., and Masson, J. Y. A Saccharomyces cerevisiae mutant defines a new locus essential for resistance to the antitumour drug bleomycin. Can. J. Microbiol., 42: 835-843, 1996.
26. Biersack, H., Jensen, S., Gromova, I., Nielsen, I. S., Westergaard, O., and Andersen, A. H. Active heterodimers are formed from human DNA topoisomerase II α and II β isoforms. Proc. Natl. Acad. Sci. USA, 93: 8288-8293, 1996.
27. Adachi, N., Miyaike, M., Kato, S., Kanamaru, R., Koyama, H., and Kikuchi, A. Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain. Nucleic Acids Res., 25: 3135-3142, 1997.
28. Kirsch, D. R. Development of improved cell-based assays and screens in Saccharomyces through the combination of molecular and classical genetics. Curr. Opin. Biotechnol., 4: 543-552, 1993.
29. Nitiss, J., and Wang, J. C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA, 85: 7501-7505, 1988.
30. Wasserman, R. A., Austin, C. A., Fisher, L. M., and Wang, J. C. Use of yeast in the study of anticancer drugs targeling DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase IIα in yeast. Cancer Res., 53: 3591-3596, 1993.
31. Worland, S. T., and Wang, J. C. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J. Biol. Chem., 264: 4412-4416, 1989.
32. Capranico, G., Kohn, K. W., and Pommier, Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res., 18: 6611-6619, 1990.
33. Capranico, G., Soranzo, C., and Zunino, F. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. Cancer Res., 46: 5499-5503, 1986.
34. Jensen, S., Redwood, C. S., Jenkins, J. R., Andersen, A. H., and Hickson, I. D. Human DNA topoisomerases IIα and IIβ can functionally substitute for yeast TOP2 in chromosome segregation and recombination. Mol. Gen. Genet., 252: 79-86, 1996.
35. Meczes, E. L., Marsh, K. L., Fisher, L. M., Rogers, M. P., and Austin, C. A. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 β construct allows the study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother. Pharmacol., 39: 367-375, 1997.
36. Binaschi, M., Capranico, G., Dal Bo, L., and Zunino, F. Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity. Mol. Pharmacol., 51: 1053-1059, 1997.
37. Capranico, G., Supino, R., Binaschi, M., Capolongo, L., Grandi, M., Suarato, A., and Zunino, F. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol. Pharmacol., 45: 908-915, 1994.
38. Capranico, G., Butelli, E., and Zunino, F. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety. Cancer Res., 55: 312-317, 1995.
39. Pommier, Y., Orr, A., Kohn, K. W., and Riou, J. F. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Cancer Res., 52: 3125-3130, 1992.
40. Borgnetto, M. E., Zunino, F., Tinelli, S., Kas, E., and Capranico, G. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility. Cancer Res., 56: 1855-1862, 1996.
41. Bjornsti, M. A., Benedetti, P., Viglianti, G. A., and Wang, J. C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res., 49: 6318-6323, 1989.
42. Ishida, R., Hamatake, M., Wasserman, R. A., Nitiss, J., Wang, J. C., and Andoh, T. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res., 55: 2299-2303, 1995.
43. Nitiss, J. L., and Wang, J. C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol. Pharmacol., 50: 1095-1102, 1996.
44. D'Arpa, P., Beardmore, C., and Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.
45. Kule, C., Ondrejickova, O., and Verner, K. Doxorubicin, daunorubicin, and mitoxantrone cytotoxicity in yeast (published erratum appears in Mol. Pharmacol., 47: 882, 1995). Mol. Pharmacol., 46: 1234-1240, 1994.
46. Capranico, G., Riva, A., Tinelli, S., Dasdia, T., and Zunino, F. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei. Cancer Res., 47: 3752-3756, 1987.
47. Nitiss, J. L. Using yeast to study resistance to topoisomerase II-targeting drugs. Cancer Chemother. Pharmacol., 34 (Suppl.): S6-S13, 1994.
48. Woessner, R. D., Chung, T. D., Hofmann, G. A., Mattern, M. R., Mirabelli, C. K., Drake, F. H., and Johnson, R. K. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res., 50: 2901-2908, 1990.
49. Giaccone, G., van Ark-Otte, J., Scagliotti, G., Capranico, G., van der Valk, P., Rubio, G., Dalesio, O., Lopez, R., Zunino, F., Walboomers, J., and Pinedo, H. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim. Biophys. Acta, 1264: 337-346, 1995.
50. Binaschi, M., Capranico, G., De Isabella, P., Mariani, M., Supino, R., Tinelli, S., and Zunino, F. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors. Int. J. Cancer, 45: 347-352, 1990.
51. Binaschi, M., Supino, R., Gambetta, R. A., Giaccone, G., Prosperi, E., Capranico, G., Cataldo, I., and Zunino, F. MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. Int. J. Cancer, 62: 84-89, 1995.
52. Supino, R., Prosperi, E., Formelli, F., Mariani, M., and Parmiani, G. Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention. Br. J. Cancer, 54: 33-42, 1986.